Market noise is relentless. Financial headlines scream about the same handful of stocks while important opportunities—the kind that can meaningfully impact your portfolio—often fly completely under the radar.
That’s exactly why we publish this watchlist each week.
While most investors are distracted by mainstream narratives, we’re digging through earnings transcripts, analyzing technical setups, and monitoring institutional money flows to identify companies at potential inflection points. Our focus isn’t on what’s already priced in, but rather on what the market hasn’t fully appreciated yet.
Each week, we spotlight three stocks that merit your attention. We focus on opportunities where timing, valuation, and catalysts align to create potentially favorable entry points.
Our rigorous analysis goes beyond surface-level metrics to identify opportunities that most retail investors don’t have time to uncover. Each pick comes with clear reasoning, specific triggers to watch for, and a compelling risk-adjusted profile designed to help you make more informed investment decisions.
Here’s what we’re watching this week:
Credo Technology Group (CRDO) — Data Center Connectivity Play With Explosive Growth
Credo Technology represents an exceptional opportunity in AI infrastructure through its high-speed data connectivity solutions essential for data center operations as global AI data center power demand is projected to surge from 68 gigawatts in 2025 to 327 gigawatts by 2030 according to Rand Corp. Trading around $112 per share with a $20 billion market capitalization, the company provides critical wiring solutions bundling chips and ensuring efficient data center operations through its Active Electrical Cables that use signal processors to move data quickly between chips and switches while reducing signal degradation and power consumption.
The investment thesis centers on Credo’s Active Electrical Cables providing superior performance versus passive copper wiring when relaying high-speed data, creating competitive advantages as data centers prioritize efficiency and power optimization. The AEC technology addresses critical infrastructure needs as AI applications require massive data movement between GPUs, memory systems, and networking equipment—with signal integrity and power efficiency becoming increasingly important as data centers scale. By reducing both signal degradation and power consumption, Credo’s solutions deliver dual benefits of performance improvement and operating cost reduction.
The financial performance demonstrates explosive growth trajectory as fiscal Q2 2026 revenue reached $268 million, up an extraordinary 272% year-over-year, while net income of $82.6 million represented a massive swing from the $4.2 million loss in the year-ago period. The 66.76% gross margin indicates strong pricing power and favorable unit economics, while fiscal Q3 guidance projecting $335 million to $345 million revenue suggests sustained momentum with sequential growth acceleration continuing.
Recent customer wins validate the technology and market positioning as the company announced a deal with TensorWave—an AI cloud provider working exclusively with Advanced Micro Devices—to deploy Credo’s AECs on TensorWave’s next-generation AI cluster infrastructure. This partnership demonstrates Credo’s ability to win business across multiple chip ecosystems beyond just Nvidia-based systems, expanding addressable market and reducing single-customer concentration risks while validating the AEC technology’s superiority across different AI infrastructure configurations.
The broader market opportunity extends beyond current AI data center buildout as 5G deployments and high-performance computing applications also require Credo’s connectivity solutions, providing diversification beyond pure AI infrastructure exposure. The company’s positioning across data centers, 5G products, and high-performance computing creates multiple growth vectors supporting sustained revenue expansion as each segment scales independently.
For growth investors seeking AI infrastructure exposure beyond chipmakers and foundries, Credo Technology’s combination of 272% year-over-year revenue growth, profitable operations with $82.6 million quarterly net income, fiscal Q3 guidance indicating continued acceleration, Active Electrical Cable technology providing differentiated performance and power efficiency, customer wins across multiple chip ecosystems including AMD partnership, and positioning in the critical but overlooked data connectivity layer creates compelling opportunity in a company capitalizing on explosive AI data center power demand projected to grow nearly 5x by 2030.
Deere & Company (DE) — Agricultural Equipment Leader Pivoting to AI Technology
Deere & Company presents a compelling blue-chip opportunity as the agricultural machinery leader experiences a renaissance through strategic AI investments that position it as an unexpected winner from artificial intelligence adoption. Trading around $629 per share with a $171 billion market capitalization after gaining 35% year-to-date before a 5% pullback on tariff-related fears, the company dominates the market for agricultural machinery and related tools including software while leveraging its brand advantage and farmer relationships in ways typical software companies cannot replicate.
The investment thesis centers on Deere’s unique positioning combining established equipment dominance with cutting-edge AI technology integration creating defensible competitive moats. The company is investing in autonomous tractors, AI-powered cameras that identify weeds and spray herbicide with precision, and predictive maintenance systems monitoring machinery to reduce downtime—transforming traditional equipment into intelligent platforms delivering ongoing value beyond the initial purchase. This technology pivot leverages Deere’s reputation and reach with farmers who trust the brand’s century-plus history, creating barriers to entry that pure software companies cannot overcome.
The AI strategy proves particularly powerful because the technology comes bundled with equipment sales rather than requiring separate adoption decisions. Farmers purchasing Deere equipment automatically gain access to AI capabilities integrated into machinery they’re already buying, removing adoption friction while creating recurring software and service revenue streams. The autonomous tractor technology addresses critical labor shortages in agriculture while improving operational efficiency, AI-powered weed identification reduces herbicide costs and environmental impact through precision application, and predictive maintenance minimizes expensive downtime during critical planting and harvest windows.
The recurring revenue opportunity mirrors successful technology business models as AI features, software subscriptions, and ongoing service contracts create annuity-like income streams supplementing traditional equipment sales. This transformation improves business model quality through more predictable revenue, higher margins on software and services, and deeper customer relationships requiring ongoing engagement rather than transactional equipment purchases every several years.
The valuation at 34 times earnings appears elevated by historical agricultural equipment standards but seems warranted given the technology transformation and AI growth potential. The recent 5% pullback on tariff concerns creates entry opportunity as the long-term AI transformation story remains intact while near-term sentiment weighs on the stock. The 1.03% dividend yield provides modest income while management’s focus on technology investments positions the company for sustained growth rather than maximizing current distributions.
For investors seeking blue-chip exposure to AI through an unexpected angle, Deere & Company’s combination of 35% year-to-date appreciation demonstrating market recognition of AI potential, dominant agricultural equipment market share providing installed base for technology deployment, AI investments in autonomous tractors and precision agriculture creating differentiated value, brand advantage and farmer relationships preventing software company disruption, recurring revenue transformation improving business model quality, and recent pullback on tariff fears creating entry point makes the stock compelling despite elevated valuation that appears justified by the technology-driven growth trajectory transforming traditional agricultural equipment into intelligent platforms.
Medtronic (MDT) — Medical Device Giant With Surgical Robotics Catalyst
Medtronic represents an attractive sleeper opportunity as the diversified medical device leader just received FDA approval for its Hugo surgical robot in the United States with the first surgeries performed in February, positioning the company to replicate Intuitive Surgical’s extraordinary success while trading at less than half the pure-play competitor’s valuation. Trading around $98 per share with a $125 billion market capitalization at 27 times earnings and offering a 2.9% dividend yield backed by decades of annual increases, Medtronic provides compelling risk-adjusted exposure to the surgical robotics opportunity through an established company in show-me mode awaiting proof of Hugo’s commercial success.
The investment thesis centers on the massive opportunity demonstrated by Intuitive Surgical’s experience as the first mover in surgical robotics has installed over 11,100 da Vinci robots worldwide generating recurring revenue annuities since roughly 75% of revenue derives from services and instrument/accessory sales rather than robot purchases. This recurring revenue model creates compounding value as each installed robot generates ongoing income streams for years, with Intuitive Surgical’s success reflected in its 64 price-to-earnings ratio. If Hugo experiences similar growth trajectory, Wall Street will likely re-rate Medtronic’s valuation upward from the current 27 times earnings toward levels reflecting the surgical robotics opportunity.
The competitive positioning recognizes that healthcare innovation creates room for multiple players in most market segments including surgical robotics. Medtronic’s decades of relationships with hospitals, surgeons, and healthcare systems provide distribution advantages and credibility that startups lack, while the diversified business model spanning cardiovascular, neuroscience, and surgical markets creates cross-selling opportunities and reduces Hugo’s execution risk through established revenue streams supporting continued operations regardless of robotics adoption pace.
The valuation discount versus Intuitive Surgical appears excessive given Medtronic’s established market position, though diversification across multiple medical device categories will likely limit pure surgical robotics upside compared to a focused competitor. The company has been in a product development phase for several years with few exciting new product introductions, leaving investors in a show-me mood regarding innovation and growth acceleration. Hugo could fundamentally change this narrative by demonstrating Medtronic’s ability to compete in cutting-edge medical technology while the February timing of first U.S. surgeries means early performance data should emerge over coming quarters providing visibility into commercial traction.
The dividend component differentiates Medtronic from Intuitive Surgical as the 2.9% yield backed by decades of annual increases provides income while investors wait for Hugo’s commercial success to materialize. This combination of current income and growth optionality appeals to dividend growth investors seeking reasonable current yield with potential for capital appreciation as surgical robotics gains traction and Wall Street recognizes the opportunity.
For investors seeking surgical robotics exposure at half the valuation of the pure-play leader, Medtronic’s combination of Hugo FDA approval with first surgeries completed in February creating near-term catalyst, 27 times earnings versus Intuitive Surgical’s 64 times suggesting significant valuation re-rating potential if Hugo succeeds, established healthcare relationships and diversified business reducing execution risk, 2.9% dividend yield providing income while growth story develops, and show-me investor sentiment creating entry opportunity before commercial success proves out makes the stock compelling sleeper opportunity that could surge as Wall Street recognizes the surgical robotics potential transforming growth expectations for this medical device leader.
